Friday, July 9, 2021

Another 5 years of dominance: Oncology, immunology will extend their lead as pharma’s top fields through 2025

Cancer and autoimmune diseases aren’t going anywhere. And so the scramble to develop next-gen treatments rages on.

As a result, global spending on oncology and immunology medicines will significantly grow through 2025 as those treatment areas widen their lead as healthcare’s top two fields, the IQVIA Institute for Human Data Science found in a recent report.

A look at the best-selling pharmaceuticals for 2020 offers clear evidence of the dominance by the fields. Oncology and immunology meds represented 13 of the world’s bestselling 20 products from 2020, led by AbbVie’s Humira, Merck’s Keytruda and Bristol Myers Squibb’s Revlimid.

While spending on many other disease areas is expected to increase by up to 5% annually over the next few years, it won’t measure up to the 9% to 12% compound annual growth rate expected of oncology and immunology. Over the next several years, market watchers expect both fields to feature new launches, while more patients start taking up existing medicines.

By 2025, IQVIA sees annual spending on oncology reaching $273 billion, far outclassing any other field. Immunology will follow with $175 billion, the firm predicts.

Next in line will be antidiabetics at $148 billion and neurology therapies at $143 billion. No other therapy area will account for more than $75 billion in 2025 spending, IQVIA says.

RELATED: Just how much COVID-19 vaccine money is on the table? A whopping $157 billion through 2025, report says

With double-digit annual growth since 2013, the 2025 projection is just an extension of the long-running performance for oncology, IQVIA executive director Murray Aitken said in an interview.

“The higher growth in the last few years has been driven by the introduction of the PD-1s, PD-L1s and their use in a growing number of indications,” Aitken said. “We estimate there will be over 100 new oncology drugs launched between now and 2025.”

At the same time, IQVIA recognizes that many of those new oncology drugs will be “increasingly narrowly focused” as biomarker-driven therapies yield products that don’t translate to wider use.  

In immunology, new meds and patient uptake will drive spending growth, but biosimilars will provide an offsetting force, Aiken said. That’ll come into clear focus after Humira biosims launch in the U.S. in 2023, boosting competitive pressures.

Over the past five years, immunology spending has grown at 17% annually thanks to new, highly effective treatments for conditions such as rheumatoid arthritis, ulcerative colitis, Crohn’s disease and psoriasis. But the pace is expected to slow after 2022, thanks largely to biosims.

RELATED: Special report: Biopharma rides a new wave of targeted treatments for cancer 

One area that’s possibly under the radar? Neurology, Aitken said. New treatments for Alzheimer’s, Parkinson’s and rare diseases could spark major spending surges in the years to come.

Meanwhile, diabetes treatments appear to have reached limitations in class growth. Still, newer products such as Eli Lilly’s Trulicity and Novo’s oral GLP-1 Rybelsus are driving growth for their respective companies.

Source link

Stay Connected


Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...